Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
Authors
Keywords
-
Journal
Vaccines
Volume 10, Issue 1, Pages 72
Publisher
MDPI AG
Online
2022-01-10
DOI
10.3390/vaccines10010072
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Covid-19 vaccination: What’s the evidence for extending the dosing interval?
- (2021) Gareth Iacobucci et al. BMJ-British Medical Journal
- Could mixing COVID vaccines boost immune response?
- (2021) Heidi Ledford NATURE
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
- (2021) Xuping Xie et al. NATURE MEDICINE
- Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
- (2021) Carmen Elena Gómez et al. Vaccines
- Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
- (2021) Eleftheria Vasileiou et al. LANCET
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
- (2021) Mehrdad Mohammadi et al. Brazilian Journal of Infectious Diseases
- Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
- (2021) Yaniv Lustig et al. Eurosurveillance
- Neutralization of alpha, gamma, and D614G SARS‐CoV‐2 variants by CoronaVac vaccine‐induced antibodies
- (2021) Jorge Fernández et al. JOURNAL OF MEDICAL VIROLOGY
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- (2021) Mine Durusu Tanriover et al. LANCET
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
- (2021) David Hillus et al. Lancet Respiratory Medicine
- Principles for designing an optimal mRNA lipid nanoparticle vaccine
- (2021) Edo Kon et al. CURRENT OPINION IN BIOTECHNOLOGY
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
- (2021) Ruiqi Zhang et al. Vaccines
- Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples
- (2021) Kwok-Hung Chan et al. Diagnostics
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
- (2020) Andrew J Pollard et al. LANCET INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started